Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Echo IQ Advanced US Expansion as FDA Strategy and Funding Strengthened Growth Platform
Highlights
FY26 Marked Broader Commercial Progress
Echo IQ Limited (ASX: EIQ) released its FY26 annual report on 28 August 2026, detailing progress across commercial adoption, regulatory development and cardiovascular artificial-intelligence products. The company had increased utilisation of its FDA-cleared EchoSolv AS platform, deployed the technology within Mount Sinai Health System and expanded its engaged US pipeline to more than 70 hospitals and multi-centre health systems.
EchoSolv AS had processed more than 10,200 echocardiograms during the June 2026 quarter, representing growth of about 11% from the previous quarter and more than 400% from the prior corresponding period.
Balance Sheet and Partnerships Expanded
Echo IQ had reported AU$8.7 million in cash at 30 June 2026. After year-end, the company had secured approximately AU$110 million through an institutional placement priced at AU$1.45 per share. The funding had been intended to support US commercial expansion, customer implementation and further cardiovascular AI development.
On 2 July 2026, Echo IQ disclosed an exclusive licensing agreement with Advara HeartCare that gave the company access to as many as one million anonymised echocardiography studies. It had also progressed its relationship with Pro Medicus (ASX: PME), with arrangements involving an initial AU$10 million convertible-note investment and another AU$10 million potentially available subject to specified FDA-related milestones.
Regulatory Progress for EchoSolv HF
On 17 September 2026, Echo IQ provided a further update after the FDA issued a Not Substantially Equivalent decision on the company’s first EchoSolv HF 510(k) submission. The company had said the FDA’s cited issues related to statistical analysis supporting clinical validation rather than the underlying technology or core functionality.
Echo IQ had assessed an administrative appeal, FDA Ombudsman review and a fresh 510(k) submission as possible routes forward. The company had maintained that clearance remained achievable and said its strategic agreements had not been materially affected.
Outlook
Echo IQ had entered FY27 focused on converting its US pipeline into enterprise deployments, expanding EchoSolv AS usage and advancing EchoSolv HF through the regulatory process. Further priorities had included progressing the Pro Medicus relationship, integrating the Advara dataset and developing additional cardiovascular indications, while regulatory approval, reimbursement progress and commercial conversion remained important execution variables.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au